Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3682B combination therapy in chronic hepatitis C after direct-acting antiviral failure
2015-001483-19Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatitis C virus infection comparing MK-3682B with MK-3682B + ribavirin (2 arms). Primary endpoint: Proportion of subjects achieving SVR12. Started Oct 2015; status: completed.
02
Drugs
uprifosbuvir + grazoprevir + ruzasvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2015-001483-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001483-19.